CN116531477A - A Chinese veterinary drug oral preparation for veterinary treatment of liver diseases and its preparation method and application - Google Patents
A Chinese veterinary drug oral preparation for veterinary treatment of liver diseases and its preparation method and application Download PDFInfo
- Publication number
- CN116531477A CN116531477A CN202310527678.4A CN202310527678A CN116531477A CN 116531477 A CN116531477 A CN 116531477A CN 202310527678 A CN202310527678 A CN 202310527678A CN 116531477 A CN116531477 A CN 116531477A
- Authority
- CN
- China
- Prior art keywords
- parts
- radix
- liver diseases
- veterinary
- oral preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 48
- 208000019423 liver disease Diseases 0.000 title claims abstract description 28
- 239000000273 veterinary drug Substances 0.000 title claims abstract description 26
- 239000002994 raw material Substances 0.000 claims abstract description 23
- 210000003278 egg shell Anatomy 0.000 claims abstract description 17
- 102000002322 Egg Proteins Human genes 0.000 claims abstract description 16
- 108010000912 Egg Proteins Proteins 0.000 claims abstract description 16
- 239000003814 drug Substances 0.000 claims abstract description 16
- 241000132012 Atractylodes Species 0.000 claims abstract description 9
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 claims abstract description 8
- 239000010231 banlangen Substances 0.000 claims abstract description 7
- 239000009636 Huang Qi Substances 0.000 claims abstract description 6
- 210000000582 semen Anatomy 0.000 claims abstract 6
- 235000006484 Paeonia officinalis Nutrition 0.000 claims abstract 3
- 241001106477 Paeoniaceae Species 0.000 claims abstract 3
- 241001061264 Astragalus Species 0.000 claims description 15
- 235000006533 astragalus Nutrition 0.000 claims description 15
- 210000004233 talus Anatomy 0.000 claims description 15
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 14
- 238000000605 extraction Methods 0.000 claims description 13
- 241000411851 herbal medicine Species 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 9
- 239000000203 mixture Substances 0.000 claims description 8
- 239000007864 aqueous solution Substances 0.000 claims description 7
- 239000000463 material Substances 0.000 claims description 5
- 239000002904 solvent Substances 0.000 claims description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 4
- 239000003755 preservative agent Substances 0.000 claims description 3
- 239000000243 solution Substances 0.000 claims description 3
- 239000008367 deionised water Substances 0.000 claims description 2
- 229910021641 deionized water Inorganic materials 0.000 claims description 2
- 230000002335 preservative effect Effects 0.000 claims description 2
- 238000009472 formulation Methods 0.000 claims 6
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical group O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 claims 1
- 238000001914 filtration Methods 0.000 claims 1
- 238000002156 mixing Methods 0.000 claims 1
- 210000004185 liver Anatomy 0.000 abstract description 8
- 239000008280 blood Substances 0.000 abstract description 6
- 210000004369 blood Anatomy 0.000 abstract description 6
- 229940079593 drug Drugs 0.000 abstract description 6
- 210000003734 kidney Anatomy 0.000 abstract description 4
- 230000017531 blood circulation Effects 0.000 abstract description 3
- 241000721047 Danaus plexippus Species 0.000 abstract 1
- 239000002671 adjuvant Substances 0.000 abstract 1
- 210000000941 bile Anatomy 0.000 abstract 1
- 235000013601 eggs Nutrition 0.000 description 13
- 238000003756 stirring Methods 0.000 description 13
- 230000000052 comparative effect Effects 0.000 description 12
- 241000092665 Atractylodes macrocephala Species 0.000 description 10
- 240000007371 Cuscuta campestris Species 0.000 description 10
- 238000006243 chemical reaction Methods 0.000 description 10
- 238000004519 manufacturing process Methods 0.000 description 10
- 244000236658 Paeonia lactiflora Species 0.000 description 9
- 235000008598 Paeonia lactiflora Nutrition 0.000 description 9
- 241000407170 Curcuma Species 0.000 description 8
- 235000014375 Curcuma Nutrition 0.000 description 8
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 description 8
- 244000163122 Curcuma domestica Species 0.000 description 7
- 235000003392 Curcuma domestica Nutrition 0.000 description 7
- 230000008859 change Effects 0.000 description 7
- 235000003373 curcuma longa Nutrition 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 235000013976 turmeric Nutrition 0.000 description 7
- 239000000284 extract Substances 0.000 description 6
- 230000008569 process Effects 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 4
- 244000144972 livestock Species 0.000 description 4
- 244000144977 poultry Species 0.000 description 4
- 235000013594 poultry meat Nutrition 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 241000207901 Cuscuta Species 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 238000009395 breeding Methods 0.000 description 3
- 230000001488 breeding effect Effects 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 239000002798 polar solvent Substances 0.000 description 3
- 238000013019 agitation Methods 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 238000012937 correction Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 210000000232 gallbladder Anatomy 0.000 description 2
- 230000005484 gravity Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 239000005711 Benzoic acid Substances 0.000 description 1
- 241000110637 Cuscuta chinensis Species 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 241000334160 Isatis Species 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 230000036983 biotransformation Effects 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 229940126534 drug product Drugs 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 239000011229 interlayer Substances 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 235000013613 poultry product Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- -1 stir Substances 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9066—Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/19—Acanthaceae (Acanthus family)
- A61K36/195—Strobilanthes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/284—Atractylodes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/31—Brassicaceae or Cruciferae (Mustard family), e.g. broccoli, cabbage or kohlrabi
- A61K36/315—Isatis, e.g. Dyer's woad
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/39—Convolvulaceae (Morning-glory family), e.g. bindweed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/43—Cuscutaceae (Dodder family), e.g. Cuscuta epithymum or greater dodder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/65—Paeoniaceae (Peony family), e.g. Chinese peony
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A40/00—Adaptation technologies in agriculture, forestry, livestock or agroalimentary production
- Y02A40/70—Adaptation technologies in agriculture, forestry, livestock or agroalimentary production in livestock or poultry
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Botany (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Reproductive Health (AREA)
- Physiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Nutrition Science (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Endocrinology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
技术领域technical field
本发明属于兽药技术领域,特别是涉及一种兽用治疗肝脏疾病的中兽药口服制剂及其制备方法、应用。The invention belongs to the technical field of veterinary medicines, and in particular relates to a traditional Chinese veterinary medicine oral preparation for veterinary treatment of liver diseases, a preparation method and application thereof.
背景技术Background technique
随着我国畜牧业的快速发展和提高,人们的生活和文化水平的进一步改善,动物源性食品安全的问题也越来越多地成为了人们密切关注的核心。随着国家“减抗”、“替抗”相关政策的实施,如何保证畜禽动物源性产品的安全和质量、降低使用畜禽体内的抗生素药物的副作用和残留量是目前畜牧业养殖业亟需解决的问题。中兽药产品因其安全、有效及副作用少等优势,可有效解决上述问题,可为我国畜禽的养殖发展做出巨大的贡献。中兽药在使用过程中的优势已逐渐受到中兽药研发技术人员和中兽药畜禽生产养殖者的高度重视,其中中兽药研发技术生产和畜禽养殖用量的所占比例也逐年进一步扩大。中兽药的工业产值明显提高,正在逐步迈向百亿元的产业目标。With the rapid development and improvement of my country's animal husbandry and the further improvement of people's living and cultural standards, the issue of animal-derived food safety has increasingly become the core of people's close attention. With the implementation of relevant national policies of "reducing antibiotics" and "replacing antibiotics", how to ensure the safety and quality of livestock and poultry animal-derived products and reduce the side effects and residues of antibiotics used in livestock and poultry is an urgent issue for the animal husbandry and breeding industry. problem to be solved. Chinese veterinary drug products can effectively solve the above problems due to their advantages of safety, effectiveness and less side effects, and can make great contributions to the development of livestock and poultry breeding in my country. The advantages of Chinese veterinary medicines in the process of use have gradually been highly valued by Chinese veterinary medicine research and development technicians and livestock and poultry producers and breeders of Chinese veterinary medicines. The industrial output value of traditional Chinese veterinary medicine has increased significantly, and is gradually approaching the industrial goal of 10 billion yuan.
蛋鸡产蛋性能低下是严重危害蛋鸡养殖业的重要因素,它不仅可以导致生产性能低,禽产品质量下降,还影响人民的经济收入和对外贸易等。近年来随着我国蛋鸡养殖量的持续增加,影响蛋鸡生产性能的因素较多,如长期使用激素类药物来调控蛋鸡生产性能易使机体产生耐药性,存在残留性、毒副作用等不足。The low laying performance of laying hens is an important factor that seriously endangers the laying hen breeding industry. It can not only lead to low production performance and decline in the quality of poultry products, but also affect people's economic income and foreign trade. In recent years, with the continuous increase in the number of laying hens in my country, there are many factors affecting the production performance of laying hens. For example, long-term use of hormone drugs to regulate the production performance of laying hens will easily lead to drug resistance, residual, toxic and side effects, etc. insufficient.
发明内容Contents of the invention
针对上述问题,本发明尝试从疏肝利胆、滋养肝肾、活血化瘀等角度进行复方药物组合筛选,促进蛋鸡肝脏营养代谢和生物转化,达到提高产蛋率、改善蛋壳质量的目的。本发明的中兽药口服制剂,与郁金为君,以黄芪为臣,以板蓝根和菟丝子为佐,以白术和白芍为使,配合共奏补气养血、调理肝肾、活血化瘀、清热滋阴的作用。In view of the above problems, the present invention attempts to screen the compound drug combination from the perspectives of soothing the liver and gallbladder, nourishing the liver and kidney, promoting blood circulation and removing blood stasis, so as to promote the nutritional metabolism and biotransformation of the liver of laying hens, so as to achieve the purpose of increasing egg production rate and improving eggshell quality . The oral preparation of Chinese veterinary medicine of the present invention, with curcuma as king, astragalus as minister, Radix Radix and Cuscuta as assistant, Atractylodes macrocephala and Radix Paeoniae Alba as envoy, cooperates to invigorate qi and nourish blood, regulate liver and kidney, promote blood circulation and remove blood stasis, clear away heat and nourish The role of Yin.
本发明的第一方面在于公开一种兽用治疗肝脏疾病的中兽药口服制剂,制备的原料包括以下重量份的各组分:The first aspect of the present invention is to disclose a Chinese veterinary drug oral preparation for veterinary treatment of liver diseases. The prepared raw materials include the following components in parts by weight:
郁金20-30份,黄芪25-35份,板蓝根1-10份,菟丝子5-15份,白术1-3份、白芍1-2份。20-30 parts of curcuma, 25-35 parts of astragalus, 1-10 parts of isatidis, 5-15 parts of dodder, 1-3 parts of Atractylodes macrocephala, and 1-2 parts of white peony.
在本发明的一些实施方式中,制备的原料中,所述郁金、黄芪、板蓝根、菟丝子、白术和白芍的重量比例为1:(1-1.5):(0.1-0.4):(0.1-0.5):(0.05-0.1):(0.01-0.05)。In some embodiments of the present invention, in the prepared raw materials, the weight ratio of the turmeric, astragalus, isatis root, dodder, atractylodes rhizome and white peony root is 1: (1-1.5): (0.1-0.4): (0.1- 0.5): (0.05-0.1): (0.01-0.05).
在本发明的一些实施方式中,所述郁金、黄芪、板蓝根、菟丝子、白术和白芍的重量比例为1:(1.1-1.3):(0.1-0.3):(0.3-0.5):(0.06-0.1):(0.02-0.05)。In some embodiments of the present invention, the weight ratio of the curcuma, Radix Astragali, Banlangen, Dodder, Atractylodes Rhizome and Radix Paeoniae Alba is 1: (1.1-1.3): (0.1-0.3): (0.3-0.5): (0.06 -0.1): (0.02-0.05).
在本发明的一些实施方式中,制备的原料包括以下重量份的各组分:In some embodiments of the present invention, the prepared raw materials include the following components in parts by weight:
郁金25份,黄芪30份,板蓝根5份,菟丝子10份,白术2份、白芍1份。25 parts of turmeric, 30 parts of astragalus, 5 parts of isatidis, 10 parts of dodder, 2 parts of Atractylodes macrocephala, and 1 part of white peony.
在本发明的一些实施方式中,制备的原料还包括口服制剂辅料。In some embodiments of the present invention, the prepared raw materials also include oral preparation excipients.
在本发明的一些实施方式中,所述口服制剂辅料包括去离子水和防腐剂。In some embodiments of the present invention, the oral preparation excipients include deionized water and preservatives.
在本发明的一些实施方式中,所述郁金、黄芪、板蓝根、菟丝子、白术和白芍经极性溶剂提取得到提取物,比如水、乙醇或其水溶液等极性溶剂。In some embodiments of the present invention, the turmeric, astragalus, isatidis, dodder, atractylodes rhizome and white peony root are extracted with polar solvents, such as water, ethanol or their aqueous solutions and other polar solvents.
在本发明的一些实施方式中,所述郁金、黄芪、板蓝根、菟丝子、白术和白芍的极性溶剂提取物,以提取原液、稀释剂、浓缩液或干粉的原料形式保存。In some embodiments of the present invention, the polar solvent extracts of turmeric, astragalus, isatidis, dodder, atractylodes rhizome and white peony root are preserved in the raw material form of extraction stock solution, diluent, concentrated solution or dry powder.
本发明的第二方面在于公开第一方面所述的兽用治疗肝脏疾病的中兽药口服制剂的制备方法,包括以下步骤:The second aspect of the present invention is to disclose the preparation method of the veterinary Chinese veterinary drug oral preparation for treating liver diseases described in the first aspect, comprising the following steps:
S01,取各中草药原料,粉碎,得到提取原料;S01, taking various Chinese herbal medicine raw materials and pulverizing them to obtain raw materials for extraction;
S02,对所述提取原料进行提取,提取的溶剂为乙醇水溶液;S02, extracting the extraction raw material, the extracted solvent is ethanol aqueous solution;
S03,过滤,得到提取液;S03 is filtered to obtain the extract;
S04,加入辅料,调配,得到所述兽用治疗肝脏疾病的中兽药口服制剂。S04, add excipients, prepare, and obtain the veterinary Chinese veterinary drug oral preparation for treating liver diseases.
在本发明的一些实施方式中,S02中,所述提取的溶剂为8-10倍体积的60-80%(v/v)的乙醇水溶液。In some embodiments of the present invention, in S02, the extraction solvent is 8-10 times the volume of 60-80% (v/v) ethanol aqueous solution.
在本发明的一些实施方式中,S02中,在50-75℃下提取2-5h,优选为提取2-3次。In some embodiments of the present invention, in S02, extract at 50-75°C for 2-5 hours, preferably 2-3 times.
在本发明的一些实施方式中,在对所述提取原料进行提取的过程中,同时采用机械搅拌来提高提取效果和减少局部物料分布不均的问题。采用模糊控制算法来处理在搅拌容器中的温度传感器实时获取的温度来动态调整搅拌速度,步骤如下:In some embodiments of the present invention, during the process of extracting the extracted raw materials, mechanical agitation is used at the same time to improve the extraction effect and reduce the problem of uneven distribution of local materials. The fuzzy control algorithm is used to process the real-time temperature acquired by the temperature sensor in the stirring vessel to dynamically adjust the stirring speed, the steps are as follows:
(1)定义输入变量反应温度(T)、反应温度变化率(dT/dt)和输出变量搅拌速度(v),读取温度和温度变化率,输入到模糊控制器中;(1) Define the input variable reaction temperature (T), the reaction temperature change rate (dT/dt) and the output variable stirring speed (v), read the temperature and temperature change rate, and input them into the fuzzy controller;
(2)初始化模糊控制器,根据输入变量的隶属度函数和设定规则库,计算出每个规则的权重值和输出变量的隶属度函数,对所有规则的权重值和隶属度函数进行合取运算,得到输出隶属度函数;对输出隶属度函数进行重心计算,得到模糊输出值。(2) Initialize the fuzzy controller, calculate the weight value of each rule and the membership function of the output variable according to the membership function of the input variable and the set rule base, and combine the weight value and membership function of all rules Calculate the output membership function to obtain the output membership function; calculate the center of gravity of the output membership function to obtain the fuzzy output value.
(3)通过反模糊化转换,得到具体而切实可行的输出搅拌速度值v,将得到的搅拌速度信号输出到搅拌器控制器中,实现温度控制。(3) Through the defuzzification conversion, the specific and feasible output stirring speed value v is obtained, and the obtained stirring speed signal is output to the stirrer controller to realize temperature control.
(4)回到(1),继续等待下一个测量值反应温度f和反应温度变化率Δf。(4) Back to (1), continue to wait for the next measured value of reaction temperature f and reaction temperature change rate Δ f .
通过以下公式的自校正模糊控制来调控:Regulated by self-tuning fuzzy control with the following formula:
其中,β为自校正模糊控制的调节因子,取值为[0,1],与f,Δf相关;L为模糊控制步长,Mε和M1为温度偏差的阈值上限和下限,f(n)和f(n-1)分别为n和n-1时间的偏差,f(ΔTc,S,α)为控制修正量,ΔTc为温度目标温度与实际温度的偏差,S为加热功率,α为传质系数。Among them, β is the adjustment factor of self-calibration fuzzy control, and its value is [0, 1], which is related to f, Δ f ; L is the step size of fuzzy control, Mε and M1 are the upper and lower limits of the temperature deviation threshold, f(n ) and f(n-1) are the time deviations of n and n-1 respectively, f(ΔT c , S, α) is the control correction amount, ΔT c is the deviation between the temperature target temperature and the actual temperature, S is the heating power, α is the mass transfer coefficient.
本发明的第三方面在于公开第一方面所述的兽用治疗肝脏疾病的中兽药口服制剂在提高蛋鸡产蛋率和提高蛋壳质量中的应用。The third aspect of the present invention is to disclose the application of the veterinary Chinese veterinary drug oral preparation for treating liver diseases described in the first aspect in improving laying hen egg production rate and eggshell quality.
本发明的有益效果:Beneficial effects of the present invention:
本发明的兽用治疗肝脏疾病的中兽药口服制剂,以郁金为君,以黄芪为臣,以板蓝根和菟丝子为佐,以白术和白芍为使,疏肝利胆、滋养肝肾、活血化瘀,可以很好的提高蛋鸡的产蛋率和改善蛋壳质量。The Chinese veterinary drug oral preparation for veterinary treatment of liver diseases of the present invention uses turmeric as the master, astragalus as the minister, Radix Radix and Cuscuta as assistants, Atractylodes Rhizoma Atractylodes Rhizome and Radix Paeoniae Alba as envoys, soothes the liver and gallbladder, nourishes the liver and kidney, activates blood and removes blood stasis , can very well increase the laying rate of laying hens and improve the quality of eggshells.
具体实施方式Detailed ways
以下通过特定的具体实例说明本发明的实施方式,本领域技术人员可由本说明书所揭露的内容轻易地了解本发明的其他优点与功效。本发明还可以通过另外不同的具体实施方式加以实施或应用,本说明书中的各项细节也可以基于不同观点与应用,在没有背离本发明的精神下进行各种修饰或改变。Embodiments of the present invention are described below through specific examples, and those skilled in the art can easily understand other advantages and effects of the present invention from the content disclosed in this specification. The present invention can also be implemented or applied through other different specific implementation modes, and various modifications or changes can be made to the details in this specification based on different viewpoints and applications without departing from the spirit of the present invention.
若非特别指出,实施例和对比例为组分、组分含量、制备步骤、制备参数相同的平行试验。Unless otherwise specified, examples and comparative examples are parallel tests with the same components, component contents, preparation steps, and preparation parameters.
实施例1Example 1
一种兽用治疗肝脏疾病的中兽药口服制剂的制备方法Preparation method of Chinese veterinary drug oral preparation for veterinary treatment of liver disease
(1)取郁金20份,黄芪25份,板蓝根3份,菟丝子5份,白术1份、白芍1份,粉碎,混合,得到提取原料;(1) Take 20 parts of curcuma, 25 parts of astragalus, 3 parts of Radix Radix, 5 parts of dodder, 1 part of Atractylodes macrocephala, and 1 part of Radix Paeoniae Alba, pulverize and mix to obtain raw materials for extraction;
(2)加入5倍体积70%的乙醇水溶液,搅拌,65℃下提取1h,过滤后,再次加入5倍体积70%的乙醇水溶液,搅拌,65℃下提取2h,过滤,合并两次提取的滤液;(2) Add 5 times the volume of 70% ethanol aqueous solution, stir, extract at 65°C for 1 hour, filter, add 5 times the volume of 70% ethanol aqueous solution again, stir, extract at 65°C for 2 hours, filter, and combine the two extractions filtrate;
(3)加入0.1%(w/v)的防腐剂苯甲酸,得到所述兽用治疗肝脏疾病的中兽药口服制剂。(3) adding 0.1% (w/v) preservative benzoic acid to obtain the veterinary Chinese veterinary drug oral preparation for treating liver diseases.
实施例2Example 2
一种兽用治疗肝脏疾病的中兽药口服制剂的制备方法,与实施例1的区别在于:A preparation method of Chinese veterinary drug oral preparation for veterinary treatment of liver disease, the difference from Example 1 is:
制备中的中草药原料为:郁金30份,黄芪35份,板蓝根10份,菟丝子15份,白术3份、白芍2份。The raw materials of Chinese herbal medicine in preparation are: 30 parts of curcuma, 35 parts of astragalus, 10 parts of isatidis, 15 parts of dodder, 3 parts of Atractylodes macrocephala and 2 parts of white peony.
实施例3Example 3
一种兽用治疗肝脏疾病的中兽药口服制剂的制备方法,与实施例1的区别在于:A preparation method of Chinese veterinary drug oral preparation for veterinary treatment of liver disease, the difference from Example 1 is:
制备中的中草药原料为:郁金25份,黄芪30份,板蓝根5份,菟丝子10份,白术2份、白芍1份。The raw materials of Chinese herbal medicine in preparation are: 25 parts of curcuma, 30 parts of astragalus, 5 parts of isatidis, 10 parts of dodder, 2 parts of Atractylodes macrocephala and 1 part of white peony.
实施例4Example 4
一种兽用治疗肝脏疾病的中兽药口服制剂的制备方法,与实施例1的区别在于:在对所述提取原料进行提取的过程中,同时采用机械搅拌来提高提取效果和减少局部物料分布不均的问题。采用模糊控制算法来处理在搅拌容器中的温度传感器实时获取的温度来动态调整搅拌速度,步骤如下:A preparation method of an oral Chinese veterinary medicine for treating liver diseases, the difference from Example 1 is that in the process of extracting the extracted raw materials, mechanical agitation is used to improve the extraction effect and reduce the uneven distribution of local materials. average problem. The fuzzy control algorithm is used to process the real-time temperature acquired by the temperature sensor in the stirring vessel to dynamically adjust the stirring speed, the steps are as follows:
(1)定义输入变量反应温度(T)、反应温度变化率(dT/dt)和输出变量搅拌速度(v),读取温度和温度变化率,输入到模糊控制器中;(1) Define the input variable reaction temperature (T), the reaction temperature change rate (dT/dt) and the output variable stirring speed (v), read the temperature and temperature change rate, and input them into the fuzzy controller;
(2)初始化模糊控制器,根据输入变量的隶属度函数和设定规则库,计算出每个规则的权重值和输出变量的隶属度函数,对所有规则的权重值和隶属度函数进行合取运算,得到输出隶属度函数;对输出隶属度函数进行重心计算,得到模糊输出值。(2) Initialize the fuzzy controller, calculate the weight value of each rule and the membership function of the output variable according to the membership function of the input variable and the set rule base, and combine the weight value and membership function of all rules Calculate the output membership function to obtain the output membership function; calculate the center of gravity of the output membership function to obtain the fuzzy output value.
(3)通过反模糊化转换,得到具体而切实可行的输出搅拌速度值v,将得到的搅拌速度信号输出到搅拌器控制器中,实现温度控制。(3) Through the defuzzification conversion, the specific and feasible output stirring speed value v is obtained, and the obtained stirring speed signal is output to the stirrer controller to realize temperature control.
(4)回到(1),继续等待下一个测量值反应温度和反应温度变化率。(4) Back to (1), continue to wait for the next measured value of reaction temperature and reaction temperature change rate.
通过以下公式的自校正模糊控制来调控:Regulated by self-tuning fuzzy control with the following formula:
其中,β为自校正模糊控制的调节因子,取值为[0,1],与f,Δf相关;L为模糊控制步长,Mε和M1为温度偏差的阈值上限和下限,f(n)和f(n-1)分别为n和n-1时间的偏差,f(ΔTc,S,α)为控制修正量,ΔTc为温度目标温度与实际温度的偏差,S为加热功率,α为传质系数。Among them, β is the adjustment factor of self-calibration fuzzy control, and its value is [0, 1], which is related to f, Δ f ; L is the step size of fuzzy control, Mε and M1 are the upper and lower limits of the temperature deviation threshold, f(n ) and f(n-1) are the time deviations of n and n-1 respectively, f(ΔT c , S, α) is the control correction amount, ΔT c is the deviation between the temperature target temperature and the actual temperature, S is the heating power, α is the mass transfer coefficient.
结果发现,对于300目以下的郁金、黄芪、板蓝根、菟丝子、白术和白芍微粉,在8倍体积的乙醇水溶液提取溶剂的夹层加热棒加热的三桨搅拌体系中,在反应器的底部紧靠测定环形设置至少3个温度传感器,获取温度和温度变化率,2个温度传感器的温差大于0.2℃或者升温速度大于5℃/min,搅拌器增加速度5%。可以显著避免提取液颜色的异常加深和副产物产生。As a result, it was found that for turmeric, astragalus, Radix Radix Radix, Cuscutae, Atractylodes macrocephala, and Radix Paeoniae Alba micropowders below 300 mesh, in the three-blade stirring system heated by the interlayer heating rod of the ethanol aqueous solution extraction solvent of 8 times the volume, the bottom of the reactor was tightly Set at least 3 temperature sensors in a ring to obtain temperature and temperature change rate. The temperature difference between the 2 temperature sensors is greater than 0.2°C or the temperature rise rate is greater than 5°C/min, and the increase rate of the stirrer is 5%. The abnormal deepening of the color of the extract and the generation of by-products can be significantly avoided.
对比例1Comparative example 1
一种兽用治疗肝脏疾病的中兽药口服制剂的制备方法,与实施例1的区别在于:A preparation method of Chinese veterinary drug oral preparation for veterinary treatment of liver disease, the difference from Example 1 is:
制备中的中草药原料为:郁金35份,黄芪10份,板蓝根3份,菟丝子5份,白术1份、白芍1份。The raw materials of Chinese herbal medicine in the preparation are: 35 parts of curcuma, 10 parts of astragalus, 3 parts of Radix Radix, 5 parts of dodder, 1 part of Atractylodes macrocephala and 1 part of white peony.
对比例2Comparative example 2
一种兽用治疗肝脏疾病的中兽药口服制剂的制备方法,与实施例1的区别在于:A preparation method of Chinese veterinary drug oral preparation for veterinary treatment of liver disease, the difference from Example 1 is:
制备中的中草药原料为:郁金20份,黄芪25份,板蓝根6份,菟丝子1份,白术1份、白芍1份。The raw materials of Chinese herbal medicine in preparation are: 20 parts of curcuma, 25 parts of astragalus, 6 parts of isatidis, 1 part of dodder, 1 part of Atractylodes macrocephala and 1 part of white peony.
对比例3Comparative example 3
一种兽用治疗肝脏疾病的中兽药口服制剂的制备方法,与实施例1的区别在于:A preparation method of Chinese veterinary drug oral preparation for veterinary treatment of liver disease, the difference from Example 1 is:
制备中的中草药原料为:郁金20份,黄芪25份,板蓝根3份,菟丝子5份,白术2份。The raw materials of Chinese herbal medicine in the preparation are: 20 parts of turmeric, 25 parts of astragalus, 3 parts of Radix Radix, 5 parts of Cuscuta, and 2 parts of Atractylodes macrocephala.
实验例对蛋鸡产蛋的影响Effects of Experimental Examples on Egg Production of Laying Hens
试验对象:48周龄的京白1号蛋鸡Test object: 48-week-old Jingbai No. 1 laying hens
饲喂和管理:蛋鸡自由采食和饮水,鸡舍正常通风和补光。对照组饲喂基础日粮,试验组的基础日粮中添加相当于0.5g/kg生药的实施例和对比例的中兽药口服制剂(可以适当浓缩体积)。Feeding and management: Layers have free access to food and water, and the chicken house is normally ventilated and supplemented with light. The control group was fed with basal rations, and the basal rations of the test group were supplemented with Chinese veterinary drug oral preparations equivalent to 0.5 g/kg crude drug of the examples and comparative examples (can be appropriately concentrated in volume).
每个试验组和对照组的蛋鸡不少于50只。There were no less than 50 laying hens in each test group and control group.
统计四周后蛋鸡的产蛋量和蛋壳质量,结果表1和表2。产蛋率=日产蛋数/总蛋鸡×100%,平均蛋重=总蛋重/总蛋数。蛋壳厚度使用游标卡尺测量鸡蛋蛋壳(去黏膜)尖端、钝端、侧端的厚度,计算平均值。蛋壳强度使用蛋壳强度测定仪(蛋壳强度测定仪ORKA)进行检测。Count the egg production and eggshell quality of laying hens after four weeks, and the results are shown in Table 1 and Table 2. Egg production rate = number of eggs laid per day/total number of laying hens × 100%, average egg weight = total egg weight/total number of eggs. Eggshell thickness Use a vernier caliper to measure the thickness of the tip, blunt end, and side end of the eggshell (remove the mucous membrane) of the egg, and calculate the average value. Eggshell strength was tested using an eggshell strength tester (eggshell strength tester ORKA).
表1产蛋性能Table 1 egg production performance
研究发现,实施例1-3的产蛋率和平均蛋重均显著优于对比例1,对比例1又显著优于对比例2、3和空白对照组。结果表明,本发明的中兽药口服制剂得到中草药组分和含量显著影响蛋鸡的产蛋性能。The study found that the egg production rate and average egg weight of Examples 1-3 were significantly better than those of Comparative Example 1, and Comparative Example 1 was significantly better than Comparative Examples 2, 3 and the blank control group. The results show that the composition and content of Chinese herbal medicine obtained in the oral preparation of Chinese veterinary medicine of the present invention significantly affect the laying performance of laying hens.
表2蛋壳质量Table 2 eggshell quality
研究发现,实施例1-3的蛋壳厚度和蛋壳强度均显著优于对比例1-3和空白对照组。结果表明,本发明的中兽药口服制剂得到中草药组分和含量显著影响蛋鸡的蛋壳质量。The research found that the eggshell thickness and eggshell strength of Examples 1-3 were significantly better than those of Comparative Examples 1-3 and the blank control group. The results show that the Chinese herbal medicine components and contents obtained in the oral preparation of the Chinese veterinary medicine of the present invention significantly affect the eggshell quality of laying hens.
以上对本发明优选的具体实施方式和实施例作了详细说明,但是本发明并不限于上述实施方式和实施例,在本领域技术人员所具备的知识范围内,还可以在不脱离本发明构思的前提下作出各种变化。The preferred specific implementations and examples of the present invention have been described in detail above, but the present invention is not limited to the above-mentioned implementations and examples. Within the scope of knowledge of those skilled in the art, it is also possible to Various changes are made.
Claims (10)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310527678.4A CN116531477B (en) | 2023-05-11 | 2023-05-11 | A Chinese veterinary oral preparation for treating liver diseases and its preparation method and application |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310527678.4A CN116531477B (en) | 2023-05-11 | 2023-05-11 | A Chinese veterinary oral preparation for treating liver diseases and its preparation method and application |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN116531477A true CN116531477A (en) | 2023-08-04 |
| CN116531477B CN116531477B (en) | 2025-02-25 |
Family
ID=87448498
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202310527678.4A Active CN116531477B (en) | 2023-05-11 | 2023-05-11 | A Chinese veterinary oral preparation for treating liver diseases and its preparation method and application |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN116531477B (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104623535A (en) * | 2015-01-14 | 2015-05-20 | 中国农业科学院兰州畜牧与兽药研究所 | Traditional Chinese medicine composition for treating egg drop disease of laying hen and preparation method and application thereof |
| CN105381410A (en) * | 2015-12-18 | 2016-03-09 | 徐静 | Traditional Chinese medicinal preparation for treating hepatitis |
| CN111388613A (en) * | 2020-05-19 | 2020-07-10 | 山西中医药大学 | Traditional Chinese veterinary medicine astragalus root compound particles for promoting growth and enhancing immunity |
-
2023
- 2023-05-11 CN CN202310527678.4A patent/CN116531477B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104623535A (en) * | 2015-01-14 | 2015-05-20 | 中国农业科学院兰州畜牧与兽药研究所 | Traditional Chinese medicine composition for treating egg drop disease of laying hen and preparation method and application thereof |
| CN105381410A (en) * | 2015-12-18 | 2016-03-09 | 徐静 | Traditional Chinese medicinal preparation for treating hepatitis |
| CN111388613A (en) * | 2020-05-19 | 2020-07-10 | 山西中医药大学 | Traditional Chinese veterinary medicine astragalus root compound particles for promoting growth and enhancing immunity |
Non-Patent Citations (3)
| Title |
|---|
| 刘静;朱盛山;罗裕;张学沛;彭亮;黄娟萍;蔡延渠;: "中草药在养鸡业中的应用概述", 中兽医学杂志, no. 06, 15 December 2013 (2013-12-15), pages 49 - 52 * |
| 戴敏, 刘青云, 訾晓梅, 彭代银: "强肝糖浆对大鼠四氯化碳慢性肝损伤的保护作用", 基层中药杂志, vol. 16, no. 04, 15 August 2001 (2001-08-15), pages 12 - 13 * |
| 李骁驽;: "中草药饲料添加剂在商品蛋鸡生产中的应用", 兽药与饲料添加剂, vol. 14, no. 01, 20 February 2009 (2009-02-20), pages 23 - 25 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN116531477B (en) | 2025-02-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103478436B (en) | Chinese medicinal herb feed additive for regulating fat metabolism of Chinese softshell turtle, promoting growth and enhancing immunity and feed containing same | |
| CN107349385A (en) | One group is used for fermented tcm composition that live pig nonreactive cultivates and preparation method thereof | |
| CN101744923B (en) | Traditional Chinese medicine compound pharmaceutical composition used for laying fowls and preparation method and application thereof | |
| CN104187091B (en) | A kind of common eel compound Chinese herbal medicine additive of disease-resistant growth-promoting | |
| CN101427731A (en) | Diarrhea resistant composite Chinese herbal medicine feed additive for pigling | |
| CN101181496B (en) | Medicine for preventing and treating infectious bronchitis of chicken | |
| CN104489417A (en) | Chinese herbal medicine feed additive capable of promoting growth of muscles of broiler chickens | |
| CN110522885B (en) | Chinese herbal medicine premix for improving reproductive performance of sows and preparation method thereof | |
| CN110664950A (en) | A kind of soft-shelled turtle Chinese herbal medicine feed additive | |
| CN1899530A (en) | Medicine for preventing and treating infectious laryngotracheitis of chicken | |
| CN112807348B (en) | Disease-resistant and growth-promoting traditional Chinese medicine compound, and preparation and application thereof | |
| CN106360142A (en) | Chinese herbal medicine feed additive capable of controlling diseases and promoting growth for penaeus vannamei and preparation method of additive | |
| CN102813850B (en) | Traditional Chinese medicine composition for preventing and treating poultry coccidiosis and preparation method of traditional Chinese medicine composition | |
| CN116531477A (en) | A Chinese veterinary drug oral preparation for veterinary treatment of liver diseases and its preparation method and application | |
| CN118755664A (en) | A Chinese medicine composition for improving human sperm motility, sperm culture fluid and use method thereof | |
| CN116898027A (en) | Chinese herbal medicine feed additive and preparation method thereof | |
| CN109331111B (en) | Compound andrographis paniculata preparation for treating livestock and poultry epidemic febrile disease and preparation method thereof | |
| CN101780143A (en) | Method for producing scutellaria detoxification powder of veterinary medicament | |
| CN106472823A (en) | A kind of auxiliary feedstuff of crucian cultivation | |
| CN106309978A (en) | Traditional Chinese medicine feed additive for preventing and treating bird flu and preparation method thereof | |
| CN110679535A (en) | Breeding method for improving production performance of black-bone sheep | |
| CN105998757B (en) | A kind of traditional Chinese medicine composition for treating porcine pseudorabies and preparation method thereof | |
| CN112587636A (en) | Antiviral particle and preparation method thereof | |
| CN106551134A (en) | A kind of pigletss diarrhea feed additive and preparation method thereof, application | |
| CN116036224A (en) | Spirit-calming cream for cultivating primordial qi and preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |